Rod Humerickhouse

18.5k total citations · 6 hit papers
107 papers, 8.1k citations indexed

About

Rod Humerickhouse is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, Rod Humerickhouse has authored 107 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Genetics, 36 papers in Oncology and 34 papers in Molecular Biology. Recurrent topics in Rod Humerickhouse's work include Chronic Lymphocytic Leukemia Research (56 papers), Lymphoma Diagnosis and Treatment (24 papers) and Cancer Treatment and Pharmacology (16 papers). Rod Humerickhouse is often cited by papers focused on Chronic Lymphocytic Leukemia Research (56 papers), Lymphoma Diagnosis and Treatment (24 papers) and Cancer Treatment and Pharmacology (16 papers). Rod Humerickhouse collaborates with scholars based in United States, Australia and Germany. Rod Humerickhouse's co-authors include Sari H. Enschede, John F. Seymour, William G. Wierda, Thomas J. Kipps, Martin Dunbar, Andrew W. Roberts, Hao Xiong, John F. Gerecitano, Shekman Wong and Matthew S. Davids and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Rod Humerickhouse

106 papers receiving 8.0k citations

Hit Papers

Targeting BCL2 with Venet... 2010 2026 2015 2020 2015 2010 2011 2018 2018 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
    2015 1.3k citations Andrew W. Roberts, Matthew S. Davids et al. New England Journal of Medicine profile →
  2. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
    2010 663 citations Wyndham H. Wilson, Owen A. O’Connor et al. The Lancet Oncology profile →
  3. Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
    2011 632 citations Andrew W. Roberts, John F. Seymour et al. Journal of Clinical Oncology profile →
  4. Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
    2018 595 citations John F. Seymour, Thomas J. Kipps et al. New England Journal of Medicine profile →
  5. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
    2018 498 citations Courtney D. DiNardo, Keith W. Pratz et al. The Lancet Oncology profile →
  6. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
    2019 456 citations Andrew H. Wei, Stephen A. Strickland et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Rod Humerickhouse 3.7k 3.1k 2.4k 2.1k 2.1k 107 8.1k
Lynne V. Abruzzo 2.2k 0.6× 2.6k 0.8× 1.5k 0.6× 2.6k 1.2× 3.2k 1.5× 185 8.0k
Dolors Colomer 5.1k 1.4× 4.9k 1.6× 2.7k 1.1× 4.4k 2.0× 3.1k 1.5× 280 12.0k
Gunnar Juliusson 2.9k 0.8× 4.4k 1.4× 3.3k 1.4× 2.8k 1.3× 2.4k 1.1× 189 9.0k
Matthew S. Davids 2.2k 0.6× 4.0k 1.3× 1.6k 0.7× 3.0k 1.4× 1.8k 0.9× 261 6.9k
Beatríz Bellosillo 2.9k 0.8× 3.2k 1.0× 1.3k 0.6× 2.2k 1.1× 2.3k 1.1× 231 7.6k
John F. Gerecitano 2.2k 0.6× 1.7k 0.6× 915 0.4× 1.8k 0.8× 1.9k 0.9× 101 5.4k
Sven de Vos 2.1k 0.6× 2.6k 0.8× 1.2k 0.5× 3.9k 1.8× 3.6k 1.7× 192 7.6k
Carlo Gambacorti‐Passerini 5.0k 1.3× 5.5k 1.8× 7.9k 3.2× 1.1k 0.5× 2.9k 1.4× 342 13.7k
Thorsten Zenz 2.4k 0.6× 3.6k 1.1× 951 0.4× 2.6k 1.2× 1.4k 0.7× 166 6.5k
Jason Gotlib 4.0k 1.1× 5.0k 1.6× 5.3k 2.2× 595 0.3× 1.3k 0.6× 297 11.0k

Countries citing papers authored by Rod Humerickhouse

Since Specialization
Citations

This map shows the geographic impact of Rod Humerickhouse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rod Humerickhouse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rod Humerickhouse more than expected).

Fields of papers citing papers by Rod Humerickhouse

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rod Humerickhouse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rod Humerickhouse. The network helps show where Rod Humerickhouse may publish in the future.

Co-authorship network of co-authors of Rod Humerickhouse

This figure shows the co-authorship network connecting the top 25 collaborators of Rod Humerickhouse. A scholar is included among the top collaborators of Rod Humerickhouse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rod Humerickhouse. Rod Humerickhouse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gan, Hui, Matthew Burge, Benjamin Solomon, et al.. (2021). A Phase 1 and Biodistribution Study of ABT-806i, an 111In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806. Journal of Nuclear Medicine. 62(6). 787–794. 15 indexed citations
2.
Wei, Andrew H., Stephen A. Strickland, Jing-Zhou Hou, et al.. (2019). Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. Journal of Clinical Oncology. 37(15). 1277–1284. 456 indexed citations breakdown →
3.
DiNardo, Courtney D., Keith W. Pratz, Anthony Letai, et al.. (2018). Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. The Lancet Oncology. 19(2). 216–228. 498 indexed citations breakdown →
4.
Wierda, William G., Matthew S. Davids, Richard R. Furman, et al.. (2017). Venetoclax (VEN) Is Active in Chronic Lymphocytic Leukemia (CLL) Relapsed or Refractory to More Than One B-Cell Receptor Pathway Inhibitor (BCRi). Blood. 130. 3025–3025. 3 indexed citations
5.
6.
Gan, Hui, Matthew Burge, Benjamin Solomon, et al.. (2017). A Phase 1 and Biodistribution Study of Abt-806I, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-Egfr Antibody Abt-806. Internal Medicine Journal. 47. 13–13. 2 indexed citations
7.
8.
Agarwal, Suresh, Courtney D. DiNardo, Jalaja Potluri, et al.. (2017). Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments. Clinical Therapeutics. 39(2). 359–367. 167 indexed citations
9.
Jones, Jeffrey A., Anthony R. Mato, William G. Wierda, et al.. (2017). Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. The Lancet Oncology. 19(1). 65–75. 262 indexed citations
10.
Roberts, Andrew W., Matthew S. Davids, John M. Pagel, et al.. (2015). Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine. 374(4). 311–322. 1337 indexed citations breakdown →
11.
Cleary, James M., David A. Reardon, Nilofer S. Azad, et al.. (2015). A phase 1 study of ABT-806 in subjects with advanced solid tumors. Investigational New Drugs. 33(3). 671–678. 28 indexed citations
12.
Yang, Jianning, Peter Noertersheuser, Sven Mensing, et al.. (2014). Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia. Cancer Chemotherapy and Pharmacology. 74(3). 593–602. 118 indexed citations
13.
Wilson, Wyndham H., Owen A. O’Connor, Myron S. Czuczman, et al.. (2010). Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. The Lancet Oncology. 11(12). 1149–1159. 663 indexed citations breakdown →
14.
Thng, Choon Hua, Tong San Koh, Septian Hartono, et al.. (2007). Dynamic contrast enhanced MRI (DCE-MRI) for assessment of effects of anti-angiogenic therapy: Comparison of the transfer constant (Ktrans) to blood flow and permeability derived by a distributed parameter model. Clinical Cancer Research. 13. 1 indexed citations
15.
McKeegan, Evelyn, Dawn M. Carlson, Raymond A. Knight, et al.. (2006). Characterization of human circulating endothelial cells to monitor response to antitumor therapy in human clinical trials. Clinical Cancer Research. 12. 1 indexed citations
16.
Hoekstra, Ronald, Filip De Vos, Ferry A.L.M. Eskens, et al.. (2006). Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: A safe combination. European Journal of Cancer. 42(4). 467–472. 38 indexed citations
17.
Gietema, Jourik A., Ronald Hoekstra, Filip De Vos, et al.. (2006). A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors. Annals of Oncology. 17(8). 1320–1327. 39 indexed citations
18.
Bidasee, Keshore R., Henry R. Besch, Koert Gerzon, & Rod Humerickhouse. (1995). Activation and deactivation of sarcoplasmic reticulum calcium release channels: Molecular dissection of mechanisms via novel semi-synthetic ryanoids. Molecular and Cellular Biochemistry. 149-150(1). 145–160. 9 indexed citations
19.
20.
Gerzon, Koert, Rod Humerickhouse, Henry R. Besch, et al.. (1993). Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum calcium (2+)-release channel. Journal of Medicinal Chemistry. 36(10). 1319–1323. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lynne V. Abruzzo Breakdown of academic impact, for papers by Dolors Colomer Breakdown of academic impact, for papers by Gunnar Juliusson Breakdown of academic impact, for papers by Matthew S. Davids Breakdown of academic impact, for papers by Beatríz Bellosillo Breakdown of academic impact, for papers by John F. Gerecitano Breakdown of academic impact, for papers by Sven de Vos Breakdown of academic impact, for papers by Carlo Gambacorti‐Passerini Breakdown of academic impact, for papers by Thorsten Zenz Breakdown of academic impact, for papers by Jason Gotlib
Rankless by CCL
2026